Entries by april@madhedgefundtrader.com

April 5, 2024

Mad Hedge Technology Letter April 5, 2024 Fiat Lux   Featured Trade: (DELL IS NOT A DINOSAUR ANYMORE) (DELL), (AMD), (NVDA)

Dell Is Not A Dinosaur Anymore

Investors are looking through any bad part of Dell’s business because they have faith in the AI narrative. Dell is one of those legacy companies that produce a great deal of enterprise products. The stock went nowhere for a long time but now it is different. Mixed into their earnings story was a torrent of

April 5, 2024

  (SUMMARY OF JOHN’S APRIL 3, 2024 WEBINAR) April 5, 2024   Hello everyone. TITLE The Three Margarita Webinar PERFORMANCE April – 2.00% MTD Average annualized return: +51.40 for 16 years. Trailing one-year return: +46.58% PORTFOLIO Risk On (FCX) 4/$37-$40 call spread 10%. (XOM) 4/$100-$105 call spread 10%. (OXY) 4/$59-$62 call spread 10%. (WPM) 4/$39-$42

, ,

April 5, 2024

Global Market Comments April 5, 2024 Fiat Lux   Featured Trade: (APRIL 3 BIWEEKLY STRATEGY WEBINAR Q&A), (TSLA), (TLT), (GOLD), (GLD), (WPM), (NVDA), (OXY), (XOM)

,

April 3 Biweekly Strategy Webinar Q&A

Below please find subscribers’ Q&A for the April 3 Mad Hedge Fund Trader Global Strategy Webinar, broadcast from Key West, Florida. Q: What’s going on with gold (GLD)? A: Well it’s simple; gold hasn’t moved in a year and people want to rotate out of big tech into something that hasn’t moved. Gold has a

Trade Alert - (NVDA) April 4, 2024 - BUY

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline.

April 4, 2024

Mad Hedge Biotech and Healthcare Letter April 4, 2024 Fiat Lux   Featured Trade: (A HIGH RISK, HIGH REWARD BIOTECH) (VYGR), (SNY), (ABBV), (NBIX), (NVS), (AZN), (SGMO), (BIIB), (RHHBY), (IONS)

A High Risk, High Reward Biotech

Voyager Therapeutics (VYGR) has put investors through the wringer. Since going public in 2015, their chips have swung wildly, from a high-rolling $30 down to a "you've got to be kidding me" $2.50. Why? Well, their early bet on curing neurological diseases hit some snags. But, things seem to be turning around for them these

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.